|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lei S, Zheng R, Zhang S, Wang S, Chen R,
Sun K, Zeng H, Zhou J and Wei W: Global patterns of breast cancer
incidence and mortality: A population-based cancer registry data
analysis from 2000 to 2020. Cancer Commun (Lond). 41:1183–1194.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cardoso F, Paluch-Shimon S, Senkus E,
Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya
GS, Biganzoli L, et al: 5th ESO-ESMO international consensus
guidelines for advanced breast cancer (ABC 5). Ann Oncol.
31:1623–1649. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Miller KD, Nogueira L, Mariotto AB,
Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel
RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J
Clin. 69:363–385. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Biswenger V, Baumann N, Jürschick J, Häckl
M, Battle C, Schwarz J, Horn E and Zantl R: Characterization of
EGF-guided MDA-MB-231 cell chemotaxis in vitro using a
physiological and highly sensitive assay system. PLoS One.
13(e0203040)2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Dey A, Islam SMA, Patel R and
Acevedo-Duncan M: The interruption of atypical PKC signaling and
Temozolomide combination therapy against glioblastoma. Cell Signal.
77(109819)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rosales-Soto G, Diaz-Vegas A, Casas M,
Contreras-Ferrat A and Jaimovich E: Fibroblast growth factor-21
potentiates glucose transport in skeletal muscle fibers. J Mol
Endocrinol. 1:JME190210.R2. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Imamura T: The mechanisms of glucose
transporter type 4 translocation regulated by insulin receptor
signaling. Nihon Yakurigaku Zasshi. 158:169–172. 2023.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
9
|
Peng Y, Li JZ, You M and Murr MM:
Roux-en-Y gastric bypass improves glucose homeostasis, reduces
oxidative stress and inflammation in livers of obese rats and in
Kupffer cells via an AMPK-dependent pathway. Surgery. 162:59–67.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Griffiths CD, Bilawchuk LM, McDonough JE,
Jamieson KC, Elawar F, Cen Y, Duan W, Lin C, Song H, Casanova JL,
et al: IGF1R is an entry receptor for respiratory syncytial virus.
Nature. 583:615–619. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cao YJ, Li JY, Wang PX, Lin ZR, Yu WJ,
Zhang JG, Lu J and Liu PQ: PKC-ζ aggravates doxorubicin-induced
cardiotoxicity by inhibiting Wnt/β-catenin signaling. Front
Pharmacol. 13(798436)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zang G, Mu Y, Gao L, Bergh A and Landström
M: PKCζ facilitates lymphatic metastatic spread of prostate cancer
cells in a mice xenograft model. Oncogene. 38:4215–4231.
2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shelton PM, Duran A, Nakanishi Y,
Reina-Campos M, Kasashima H, Llado V, Ma L, Campos A, García-Olmo
D, García-Arranz M, et al: The secretion of miR-200s by a
PKCζ/ADAR2 signaling axis promotes liver metastasis in colorectal
cancer. Cell Rep. 23:1178–1191. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wu J, Liu S, Fan Z, Zhang L, Tian Y and
Yang R: A novel and selective inhibitor of PKC ζ potently inhibits
human breast cancer metastasis in vitro and in mice. Tumor Biol.
37:8391–8401. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Nome ME, Euceda LR, Jabeen S, Debik J,
Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B,
Yndestad A, et al: Serum levels of inflammation-related markers and
metabolites predict response to neoadjuvant chemotherapy with and
without bevacizumab in breast cancers. Int J Cancer. 146:223–235.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tarantino U, Greggi C, Cariati I, Visconti
VV, Gasparini M, Cateni M, Gasbarra E, Botta A, Salustri A and
Scimeca M: The role of PTX3 in mineralization processes and
aging-related bone diseases. Front Immunol.
11(622772)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Netti GS, Lucarelli G, Spadaccino F,
Castellano G, Gigante M, Divella C, Rocchetti MT, Rascio F, Mancini
V, Stallone G, et al: PTX3 modulates the immunoflogosis in tumor
microenvironment and is a prognostic factor for patients with clear
cell renal cell carcinoma. Aging (Albany NY). 12:7585–7602.
2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Firouzjahi A, Eris S, Jalali SF, Bijani A
and Ranaee M: Evaluation of serum pentraxin-3 level in patients
with acute myocardial infarction compared with control group. Iran
J Pathol. 16:243–247. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yadav NVS, Barcikowski A, Uehana Y, Jacobs
AT and Connelly L: Breast adipocyte co-culture increases the
expression of pro-angiogenic factors in macrophages. Front Oncol.
10(454)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Scimeca M, Antonacci C, Toschi N, Giannini
E, Bonfiglio R, Buonomo CO, Pistolese CA, Tarantino U and Bonanno
E: Breast osteoblast-like cells: A reliable early marker for bone
metastases from breast cancer. Clin Breast Cancer. 18:e659–e669.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nirgude S, Desai S, Mahadeva R, Ravindran
F and Choudhary B: ST08 altered NF-κB pathway in breast cancer
cells in vitro as revealed by miRNA-mRNA analysis and enhanced the
effect of cisplatin on tumour reduction in EAC mouse model. Front
Oncol. 112(835027)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chivot J, Ferrand N, Fert A, Van Dreden P,
Morichon R and Sabbah M: PARP inhibitor inhibits the vasculogenic
mimicry through a NF-κB-PTX3 axis signaling in breast cancer cells.
Int J Mol Sci. 23(16171)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang P, Liu Y, Lian C, Cao X, Wang Y, Li
X, Cong M, Tian P, Zhang X, Wei G, et al: SH3RF3 promotes breast
cancer stem-like properties via JNK activation and PTX3
upregulation. Nat Commun. 11(2487)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kampo S, Ahmmed B, Zhou T, Owusu L, Anabah
TW, Doudou NR, Kuugbee ED, Cui Y, Lu Z, Yan Q and Wen QP: Scorpion
venom analgesic peptide, BMK AGAP inhibits stemness, and
epithelial-mesenchymal transition by down-regulating PTX3 in breast
cancer. Front Oncol. 9(21)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chan SH, Tsai JP, Shen CJ, Liao YH and
Chen BK: Oleate-induced PTX3 promotes head and neck squamous cell
carcinoma metastasis through the up-regulation of vimentin.
Oncotarget. 8:41364–41378. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chang WC, Wu SL, Huang WC, Hsu JY, Chan
SH, Wang JM, Tsai JP and Chen BK: PTX3 gene activation in
EGF-induced head and neck cancer cell metastasis. Oncotarget.
6:7741–7757. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang X, Wang C, Guan J, Chen B, Xu L and
Chen C: Progress of breast cancer basic research in China. Int J
Biol Sci. 17:2069–2079. 2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jiang J, Jiang S, Ahumada-Canale A, Chen
Z, Si L, Jiang Y, Yang L and Gu Y: Breast cancer screening should
embrace precision medicine: Evidence by reviewing economic
evaluations in China. Adv Ther. 40:1393–1417. 2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hu T, Qiao L, Li H, Ren H, Ning Q, Zhou H,
Chen X, Sun Z and Shen L: Pentraxin 3 (PTX-3) levels in
bronchoalveolar lavage fluid as a lung cancer biomarker. Dis
Markers. 2020(4652483)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fan Z, Zheng Y, Li X, Deng X, Ba Y, Feng
K, Su J, Wang H, Suo Z and Li L: Promoting role of pentraxin-3 in
esophageal squamous cell carcinoma. Mol Ther Oncolytics.
24:772–787. 2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Stallone G, Netti GS, Cormio L, Castellano
G, Infante B, Pontrelli P, Divella C, Selvaggio O, Spadaccino F,
Ranieri E, et al: Modulation of complement activation by
pentraxin-3 in prostate cancer. Sci Rep. 10(18400)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Falagario UG, Busetto GM, Netti GS,
Sanguedolce F, Selvaggio O, Infante B, Ranieri E, Stallone G,
Carrieri G and Cormio L: Prospective validation of pentraxin-3 as a
novel serum biomarker to predict the risk of prostate cancer in
patients scheduled for prostate biopsy. Cancers (Basel).
13(1611)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Song T, Wang C, Guo C, Liu Q and Zheng X:
Pentraxin 3 overexpression accelerated tumor metastasis and
indicated poor prognosis in hepatocellular carcinoma via driving
epithelial-mesenchymal transition. J Cancer. 9:2650–2658.
2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chang X, Li D, Liu C, Zhang Z and Wang T:
Pentraxin 3 is a diagnostic and prognostic marker for ovarian
epithelial cancer patients based on comprehensive bioinformatics
and experiments. Cancer Cell Int. 21(193)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Goulart MR, Watt J, Siddiqui I, Lawlor RT,
Imrali A, Hughes C, Saad A, ChinAleong J, Hurt C, Cox C, et al:
Pentraxin 3 is a stromally-derived biomarker for detection of
pancreatic ductal adenocarcinoma. NPJ Precis Oncol.
5(61)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ke HH, Hueng DY and Tsai WC: Low
expression of pentraxin 3 and nuclear factor-like 2 implying a
relatively longer overall survival time in Gliomas. Chin J Physiol.
62:35–43. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Islam SMA, Patel R, Bommareddy RR, Khalid
KM and Acevedo-Duncan M: The modulation of actin dynamics via
atypical Protein Kinase-C activated Cofilin regulates metastasis of
colorectal cancer cells. Cell Adh Migr. 13:106–120. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Smalley T, Islam SMA, Apostolatos C,
Apostolatos A and Acevedo-Duncan M: Analysis of PKC-ζ protein
levels in normal and malignant breast tissue subtypes. Oncol Lett.
17:1537–1546. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Smalley T, Metcalf R, Patel R, Islam SMA,
Bommareddy RR and Acevedo-Duncan M: The atypical protein kinase C
small molecule inhibitor ζ-Stat, and its effects on invasion
through decreases in PKC-ζ protein expression. Front Oncol.
10(209)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Patel R, Islam SA, Bommareddy RR, Smalley
T and Acevedo-Duncan M: Simultaneous inhibition of atypical protein
kinase-C and mTOR impedes bladder cancer cell progression. Int J
Oncol. 56:1373–1386. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kay RR, Langridge P, Traynor D and Hoeller
O: Changing directions in the study of chemotaxis. Nat Rev Mol Cell
Biol. 9:455–463. 2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sun R, Gao P, Chen L, Ma D, Wang J,
Oppenheim JJ and Zhang N: Protein kinase C ζ is required for
epidermal growth factor-induced chemotaxis of human breast cancer
cells. Cancer Res. 65:1433–1441. 2005.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Ghatak S, Misra S, Moreno-Rodrigue RA,
Hascall VC, Leone GW and Markwald RR: Periostin/β1integrin
interaction regulates p21-activated kinases in valvular
interstitial cell survival and in actin cytoskeleton
reorganization. Biochim Biophys Acta Gen Subj. 1863:813–829.
2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wu YQ, Ju CL, Wang BJ and Wang RG: PABPC1L
depletion inhibits proliferation and migration via blockage of AKT
pathway in human colorectal cancer cells. Oncol Lett. 17:3439–3445.
2019.PubMed/NCBI View Article : Google Scholar
|
